Click Here to
News, Updates,
& More
Stay Up
to Date

Conference Correspondent

Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy.
Pharmacokinetic analysis of daratumumab as part of combination regimens identified no clinical or demographic characteristics that altered exposure and activity of the monoclonal antibody. The findings support the body-weight–based dosing of 16 mg/kg.
Data from a “real-world” historical cohort of heavily pretreated patients in the Czech Republic confirmed the benefits shown in clinical trials of single-agent daratumumab compared with treatment by physician’s choice.
As out-of-pocket costs continue to rise, patients and healthcare stakeholders are increasingly concerned about the relative value of different treatment options. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.

By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.

Leslie Lauersdorf discusses her perceptions regarding daratumumab therapy and identifies how her patients have benefited from this treatment option.
Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy.
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects.
Page 7 of 16
Results 61 - 70 of 152